Skip to main content
Equibles
EVMN logo

EVMN · Evommune, Inc.

Track EVMN — free

Use EVMN with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$12.27 +0.27 (+2.25%) At close · Sep 4
Russell 2000 member Rebalance outlook locked
Market Cap
$445.30M
Shares
36.29M

EVMN metrics

57 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$12.27
Market cap
$445.30M

Price action

19 metrics
Price change (1W)
-7.3%
Price change (30D)
-12.8%
Price change (3M)
-38.4%
Price change (6M)
-53.7%
Price change (YTD)
-28.3%
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
123.4%
Beta
1.2
RSI (14D)
39.9
Price vs SMA 50
-6.6%
Price vs SMA 200
-38.4%
Avg volume (3M)
782,154
Relative volume
0.3
Average dollar volume
$11.74M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
36.29M

Valuation

12 metrics
P / E (TTM)
2.2
Trailing earnings · reciprocal yield 45.1%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
44.5×
reciprocal yield 2.2%
P / book
1.6
reciprocal yield 62.3%
FCF yield
-16.8%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-21.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-03-05

Profitability

9 metrics
Gross margin
—
Operating margin
-1,018.9%
Trailing 12 months
Net margin
-946.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$101.89M
Net income (TTM)
−$94.67M
Trailing 12 months
Diluted EPS (TTM)
$5.53
FCF margin
-746.5%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-92.97

Growth

11 metrics
Revenue growth YoY
+85.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$10.00M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2,245.4%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-34.1%
Return on assets
-31.4%
Debt / equity
—
Current ratio
11.7
EBITDA (TTM)
−$101.29M
Free cash flow (TTM)
−$74.65M
Quick ratio
11.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$200.79M
Latest balance sheet
Cash & equivalents
$60.03M
Total assets
$301.95M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$74.15M
Capital expenditures (TTM)
$501,000
R&D (TTM)
$83.77M
SG&A (TTM)
—
Stock compensation (TTM)
$12.81M
R&D / revenue
837.7%
Stock compensation / revenue
128.1%

Ownership (13F)

3 metrics
13F filers
107
13F filer change QoQ
+23
Institutional ownership
98.2%

Short interest

3 metrics
Short interest
12.9%
Latest settlement · 8.2 days to cover
Days to cover
8.2d
Short-squeeze score
71 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$508,737
Insider-sentiment score
85 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 2044725 CUSIP 30054Y107 13F (30d) 86 filings 86 filers Visit website Investor relations